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Abstract
Background: This study was an investigation of the effects of ingesting a daily dose of isolated glycinin soy
protein (11S globulin), in association with rosuvastatin, on the control of hypercholesterolemia in experimental
animals.
Methods: Male Wistar rats were kept in individual cages under appropriate controlled conditions of temperature,
light and humidity. The animals were divided into five groups (n = 9): 1) standard (STD): fed on casein as protein
source; 2) hypercholesterolemic (HC): STD plus 1% cholesterol and 0.5% cholic acid; 3) HC+11S:
hypercholesterolemic + glycinin (300 mg/kg/day); 4) HC+ROS: hypercholesterolemic + rosuvastatin (10 mg/kg/day);
5) HC+11S+ROS: HC diet, the 11S protein and the drug in the doses given in (3) and (4). The protein and the drug
were administered by gavage for 28 days. The results indicated that the addition of 1% cholesterol and 0.5% cholic
acid induced hypercholesterolemia in the animals without interfering with their weight gain.
Results: A single daily dose of glycinin contributed an additional 2.8% of dietary protein intake and demonstrated
its functional role, particularly in raising HDL-C, decreasing triglycerides in the liver and improving the atherogenic
index in animals exposed to a hypercholesterolemic diet.
Conclusion: Most of the beneficial effects of the isolated treatments disappeared when the drug (rosuvastatin) and
the protein (glycinin) were taken simultaneously. The association was shown not to interact additively, as noted in
the plasma levels of total cholesterol and non-HDL cholesterol, and in the significant increase of cholesterol in the
liver. Studies are in progress to identify the effects of peptides derived from the 11S globulin and their role in
cholesterol metabolism.
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Background
The nutritional properties of soybean proteins are well
known. They have also been studied in animal models
and in humans as a form of intervention, to reduce
plasma lipids (cholesterol, LDL-C, TG), in the context of
growing concern about hyperlipidemia and hypercholes-
terolemia and their consequences [1]. The quantity of
favorable experimental evidence, supported by epidemio-
logical and clinical studies, resulted in the approval of a
health claim by the FDA in 1999 [2], which suggested the
inclusion of 25 grams of soy protein in the daily diet to
reduce cardiovascular disease. More recent data confirm
this and link the consumption of soy protein with a lower
incidence of chronic diseases [3].
The main constituent of the soy proteins are the globu-
lins, divided into 2 types by their sedimentation coeffi-
cients: 7S or beta-conglycinin and 11S or glycinin. They
constitute approximately 90% of the total protein of the
seed. The whole protein isolate and b-conglycinin (7S
protein) fraction have received much greater attention in
scientific research than other protein fractions [3-6],
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despite its being a major fraction of the seed.
Studies with isolated soy protein in hypercholesterole-
mic rats indicate that, in addition to lowering serum cho-
lesterol, it decreases serum triglycerides levels. One
possible mechanism for the cholesterol lowering effect was
raised by Lovati et al. [7,8], indicating that soy protein
could modulate the levels of hepatic LDL-C receptors,
suppressed in hypercholesterolemia.
On the other hand, the advent of drugs with an inhibi-
tory effect on 3-hydroxy-3 methylglutaryl-CoA (HMG-
CoA) reductase, known as statins, to treat lipoprotein
metabolism disorders, is a significant event in the history
of prevention therapy, specifically in the prevention of
atherosclerosis, with consistent benefits with regard to car-
diovascular disease mortality [9]. In addition to reducing
LDL cholesterol and raising HDL-C levels, statins suppress
inflammation, in particular reducing C-reactive protein, a
biological marker which, when elevated, indicates a risk of
heart attack [10]. Among the statins, rosuvastatin has
shown a greater reduction of LDL-C than other statins in
clinical trials, and helps to slow the progress of athero-
sclerosis, reducing the formation of new lesions and the
incidence of coronary events [9,10].
In the study of hypercholesterolemia, it is known that
compounds present in foods, which are designated func-
tional compounds, can assist the drug to reduce and/or
prevent many metabolic disorders related to increased
lipids in the circulation. However, these compounds can
have a non-synergistic effect that affects the availability of
the drug and thus impairs therapy or reduces the effect of
functional compounds.
In order to collect evidence on this complex mechanism,
we investigated the effects of ingesting a daily dose of iso-
lated glycinin soy protein (11S protein), alone or combined
with rosuvastatin (a statin drug), on the control of
hypercholesterolemia in experimental animals.
Methods
Chemical composition of soy flour
The chemical composition of defatted soy flour was
determined by AOAC methods (1998) [11].
Isolation of 11S globulin
Commercial soy flour (grain size 60 mesh) was defatted
with hexane (ratio 1:8 w/v), stirred for a period of
4 hours at room temperature. This procedure was
repeated (ratio 1:4 w/v). Subsequently, the flour was fil-
tered and dried at room temperature for 24 hours. The
11S globulin was isolated by the procedure reported in
Nagano et al. [12], adapted by Ferreira et al. [6]. The pro-
tein content was determined by the method of Lowry et
al. [13], with bovine serum albumin as standard protein
( S i g m aC h e m i c a lC o . ,S t .L o u i s ,M O ,U S A ) .T h en u m b e r
and the molecular mass of the 11S protein subunits were
estimated by electrophoresis in 10% polyacrylamide gel
with 1% sodium dodecyl sulfate, in a discontinuous pH
system, as described by Laemmli [14], in the presence of
the reducing agent 2-mercaptoethanol. The standard
protein mixture of known molecular weights contained
phosphorylase b (97 kDa), bovine serum albumin
(66 kDa), ovalbumin (45 kDa), carbonic anhydrase
(30 kDa), soybean trypsin inhibitor (21.5 kDa) and lactal-
bumin (14.4 kDa).
Biological evaluation
Forty-five male Wistar rats (Rattus norvegicus var. albinus)
from the Central Animal House at São Paulo State Univer-
sity (UNESP) at Botucatu (SP, Brazil) were kept in a con-
trolled environment (12:12 h photoperiod, temperature
23 ± 2°C and relative humidity 60 ± 5%) in individual
metabolic cages, with free access to standard Purina
® (São
Paulo, SP, Brazil) chow and water, for approximately
14 days, to adapt to surroundings and reach an average
weight of 180 to 200 grams. They were then separated
into five dietary groups (n = 9) (Table 1): 1) standard
group (STD), given a diet containing casein as protein
source, as recommended by the American Institute of
Nutrition (AIN-93M) [15]; 2) hypercholesterolemic (HC),
given the standard diet plus 1% cholesterol and 0.5% cho-
lic acid, as described by Ferreira et al. [6]; 3) HC+11S,
given the hypercholesterolemic diet plus 11S soy protein
(300 mg/kg/day); 4) HC+ROS, given the HC diet and the
drug rosuvastatin (10 mg/kg/day); 5) HC+11S+ROS, given
the HC diet, the 11S protein and the drug. The experi-
mental period was 28 days. The glycinin soy protein and
drug were dissolved in saline and administered by gavage
daily at different periods. The procedures were performed
in accordance with the Guide for the Care and Use of
Laboratory Animals [16]. The experimental procedure was
approved by the Research Ethics Committee (Res. No. 32/
2008).
The variations in body weight and food intake were
checked daily during the 28-day period. At the end of
the experiment and after 12 hours of fasting, animals
were sacrificed by decapitation. Blood was collected into
tubes containing SST gel separator II (BD Vacutainer
®
B, Franklin Lakes, NJ, USA) and then centrifuged at 1,
900 × g for 15 minutes at 4°C. Serum was collected and
stored at -20°C for subsequent biochemical analysis. The
liver was removed, washed in saline (9 g NaCl/L),
weighed and immediately stored frozen at -20°C. The
hepatosomatic index (HSI) was calculated as (liver
weight/body weight) × 100.
Analysis of plasma and liver
Total cholesterol (TC), HDL-cholesterol (HDL-C) and
triglyceride (TG) levels were analyzed in triplicate with
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® (Laborlab
®.S ã oP a u l o .S P ,B r a z i l )e n z y m a t i c
kits. The fraction of non-HDL-C (LDL-C + VLDL-C)
was calculated from the difference between total choles-
terol and HDL-C and the atherogenic index was calcu-
lated as (TC - HDL-C)/HDL-C.
The TC and TG levels in the liver were determined as
described by Haug and Hostmark [17] and the liver bio-
chemical tests were performed as in the plasma analysis.
The hepatosomatic index (HSI) was calculated as (liver
weight/body weight × 100).
Statistical analysis
Data were analyzed with the program SigmaStat
® 3.5
(Dundas Software, Erkrath, Germany, 1999), using analysis
of variance (ANOVA) and the Student-Newman-Keuls
(SNK) test for multiple comparison between treatments.
Significance was accepted when p < 0.05. All results were
presented as mean ± standard error (SEM).
Results
T h ep r o t e i nc o n t e n to ft h ed e f a t t e ds o yf l o u ru s e dt o
extract the glycinin was 51%. According to Wolf et al.
[18], the minimum amount of protein in soy flour ranges
from 40 to 50%, depending on the amount of fat and car-
bohydrate and also the conditions of cultivation. The pro-
tein, treated with reducing agent during electrophoresis,
was resolved into bands with molecular weights ranging
from 22.07 to 58.14 kDa, as reported by Ferreira et al. [6].
According to Nagano et al. [12], the purity of the 11S glo-
bulin fraction obtained by this method is greater than 90%.
Hypercholesterolemia was induced in adult rats by
adding 1% cholesterol and 0.5% cholic acid to the stan-
dard diet AIN-93M, as proposed in [7,19-22], and this
was an effective model of hypercholesterolemia in the
groups HC, HC+11S, HC+ROS and HC+11S+ROS, as
indicated by the results described below.
After 28 days of the experiment, there was no statisti-
cal difference (p < 0.05) in weight gain among animals,
although there were differences in food consumption
between all the hypercholesterolemic groups and group
STD, as shown in Table 2. Thus, we can infer that the
supply of glycinin by gavage (300 mg/kg/day), although
it represented an addition of around 2.8% of dietary pro-
tein intake, did not lead to weight change and may be
considered a supplement that could influence lipid
metabolism.
Table 1 Compositions of experimental diets
Ingredients STD HC HC+11S HC+ROS HC+11S+ ROS
Casein
1 14.74 14.74 14.74 14.74 14.74
Starch 45.83 44.33 44.33 44.33 44.33
Starch dextrinated 15.5 15.5 15.5 15.5 15.5
Sucrose 10 10 10 10 10
Soybean oil 4 4 4 4 4
Cellulose 5 5 5 5 5
Mineral mix
2 3.5 3.5 3.5 3.5 3.5
Vitamin mixture
2 11 1 1 1
L-Cystine 0.18 0.18 0.18 0.18 0.18
Choline bitartrate 0.25 0.25 0.25 0.25 0.25
Cholesterol
3 01 1 1 1
Cholic acid
1 0 0.5 0.5 0.5 0.5
Treatment
Glycinin (mg/kg/dia) - - 300 - 300
Rosuvastatin (mg/kg/dia) - - - 10 10
STD = standard diet, AIN-93 Composition; HC = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and 0.5 g/100 g cholic acid; HC+11S = HC diet +
glycinin (300 mg/kg/day); HC+ROS = HC diet + rosuvastatin (10 mg/kg/day); HC+11S+ROS = HC diet + glycinin (300 mg/kg/day) and rosuvastatin (10 mg/kg/day).
1Sigma-Aldrich, Co., USA.
2PragSoluções
®, Co., Brazil.
3Reagen, Co., USA.
Table 2 Body weight and food intake in experimental groups
STD HC HC+11S HC+ROS HC+11S+ROS
Initial weight (g) 195.23 ± 5.03ª 196.55 ± 4.63ª 194.55 ± 3.92ª 193.6 ± 2.31ª 193.44 ± 2.35ª
Final weight (g) 287.77 ± 7.07ª 295.01 ± 5.43ª 298.53 ± 5.26ª 306.5 ± 3.79ª 301.49 ± 3.88ª
Weight gain (g/day) 3.31 ± 0.24ª 3.51 ± 0.32ª 3.71 ± 0.22ª 4.02 ± 0.11ª 3.84 ± 0.10ª
Food consumption (g/day) 15.47 ± 0.27
b 16.74 ± 0.33ª 17.27 ± 0.29
a 18.86 ± 0.14
a 18.34 ± 0.18
a
STD = standard diet, AIN-93 Composition; HC = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and 0.5 g/100 g cholic acid; HC+11S = HC diet +
glycinin (300 mg/kg/day); HC+ROS = HC diet + rosuvastatin (10 mg/kg/day); HC+11S+ROS = HC diet + glycinin (300 mg/kg/day) and rosuvastatin (10 mg/kg/day).
Values represented as mean ± SEM. Different superscript letters in same row indicate a significant difference (p < 0.05) between experimental groups.
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plasma cholesterol in the HC group, relative to the stan-
dard group, STD, showing that increased levels of choles-
terol in the diet contribute significantly to the elevation of
plasma cholesterol. Group HC+11S showed a reduction in
total cholesterol of 11.1%, compared to HC, while group
HC+ROS showed a reduction of 25.9%. These results sug-
gest that oral administration of glycinin, although less
powerfully than the drug at these doses, lowered the cho-
lesterol appreciably, since it is recognized that a 10%
reduction in serum cholesterol translates to a 15% reduc-
tion in risk of mortality from coronary heart disease [9].
The condition of hypercholesterolemia was evident in the
increased non-HDL fraction in the plasma of the HC
group, while HDL-C remained unchanged, relative to
STD. These changes resemble the typical situation of
hyperlipidemia in humans, which may be associated with a
reduction in the number of LDL-C receptors.
The HDL-C, however, showed an increase of 26.8% in
group HC+11S, relative both to the standard group STD,
and to HC. This result was significant, since the groups
HC+ROS and HC+11S+ROS showed no difference from
the HC group, and supports the hypothesis that glycinin
acts by raising HDL-C, which, by carrying cholesterol
esters from peripheral tissues to the liver, would be a
protective factor in reducing the risk of cardiac events.
HC group showed an increase of 127.1% in plasma TG,
compared to the level in the STD group. The other groups
(HC+11S, HC+ROS and HC+11S+ROS) showed a reduc-
tion of approximately 23% of the level in the HC group.
There was a significant increase (338.5%) of the non-
HDL fraction in HC, relative to the standard group STD,
while the levels in groups HC+11S and HC+ROS were
reduced by 19.88% and 28.95%, respectively, from that in
HC. However, group HC+11S+ROS did not differ from
the HC group, suggesting that the actions of the isolated
p r o t e i na n dt h ed r u gw e r en o ta d d i t i v e sw h e nt h e yw e r e
administered in combination.
In this study, the atherogenic index, a possible indica-
tor of a predisposition to heart disease, was 357.4%
higher in the HC group than in the standard group,
STD. Marked decreases of 42.2% in group HC+11S and
24.5% in HC+ROS, compared to HC, were observed in
this index, but the same response was not observed in
HC+11S+ROS, which showed, surprisingly, a greater
atherogenic index than group HC.
An increase ranging from 24% to 30% was observed in
the liver weight of groups HC, HC+11S, HC+ROS and
HC+11+ROS, compared to the standard casein group,
STD (Table 4). However, there was no significant differ-
ence among the groups HC+11S, HC+ROS and HC
+11S+ROS. Thus, both the liver weight and the hepato-
somatic index are inconclusive parameters for this ana-
lysis, as evidenced by various results described in the
literature [7,20,21,23].
The animals that received the hypercholesterolemic
diet (HC, HC+11S, HC+11S+ ROS) presented higher
levels of total cholesterol (TC) and triglycerides (TG) in
the liver than those given a standard diet (STD), as indi-
cated in Table 3. However, the reduction of serum cho-
lesterol observed in the HC+11S group, relative to the
HC group, was not reflected in the liver, as also observed
by Lovati et al. [7]. In contrast, a reduction of hepatic
cholesterol on the order of 37.3% was observed in the
HC+ROS group, relative to HC. Conversely, group HC
+11S+ROS showed a significant increase in TC relative
to HC, which denotes an interference or inhibition of the
e f f e c t so ft h ed r u gb yt h ep r e s e n c eo f1 1 Ss o yp r o t e i n ,
when both were administered together.
Hepatic TG showed a very significant increase (304.8%)
in group HC, relative to the STD group, while the other
groups (HC+11S, HC+ROS and HC+11S+ROS) showed
Table 3 Effect of diets on plasma lipid profile and hepatic lipid content in rats
STD HC HC+11S HC+ROS HC+11S+ ROS
Plasma
TC (mmol/L) 1.56 ± 0.07
b 4.24 ± 0.45ª 3.77 ± 0.41ª 3.14 ± 0.12ª 4.33 ± 0.40ª
HDL-C (mmol/L) 0.78 ± 0.03
b 0.82 ± 0.06
b 1.04 ± 0.04ª 0.73 ± 0.04
b 0.73 ± 0.08
b
non-HDL-C (mmol/L) 0.78 ± 0.04
b 3.42 ± 0.47ª 2.74 ± 0.4ª 2.43 ± 0.16ª 3.57 ± 0.42ª
TG (mmol/L) 0.48 ± 0.02
b 1.09 ± 0.12ª 0.85 ± 0.11ª 0.84 ± 0.07ª 0.81 ± 0.08ª
Liver
TC (μmol/g) 7.15 ± 0.34
d 57.66 ± 1.06
b 54.97 ± 2.12
b 36.15 ± 2.12
c 76.66 ± 2.12ª
TG (μmol/g) 14.52 ± 0.91
c 58.77 ± 3.97ª 46.48 ± 4.06
b 41.35 ± 2.43
b 46.74 ± 3.08
b
Atherogenic index 1.01 ± 0.05
c 4.62 ± 0.87
ab 2.67 ± 0.38
bc 3.49 ± 0.42
ab 5.06 ± 0.81
a
STD = standard diet, AIN-93 Composition; HC = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and 0.5 g/100 g cholic acid; HC+11S = HC diet +
glycinin (300 mg/kg/day); HC+ROS = HC diet + rosuvastatin (10 mg/kg/day); HC+11S+ROS = HC diet + glycinin (300 mg/kg/day) and rosuvastatin (10 mg/kg/day).
Values are represented as mean ± SEM. TC = total cholesterol; HDL-C = high density lipoprotein; non-HDL-C = difference between TC and HDL-C; TG =
triglycerides; atherogenic index = non-HDL-C/HDL-C. Different superscript letters in the same row indicate a significant difference (p < 0.05) between
experimental groups.
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tively, relative to HC.
Discussion
A large body of evidence indicates that the type of protein
in the diet, particularly those found in the legumes, can
affect plasma cholesterol levels in animal models and
humans [1,6,19,23-25]. Isolated soy protein has given out-
standingly positive results, particularly in studies of
hypercholesterolemic rats, where, in addition to lowering
serum cholesterol, it was observed to reduce TG [20,21].
With regard to the isolated protein fractions, the 7S globu-
lin has been studied the most [3-6,19,26,27]. Thus, we
aimed in this experiment to show the role of 11S globulin
in this context, which, in a single daily dose, resulted in a
reduction of atherogenic factors, including TC and TG.
This corroborates a published study [7] on the effect of
soy globulins in vitro and in vivo, which found that Spra-
gue-Dawley rats fed on a hypercholesterolemic diet, with
casein as the protein source, showed a reduction in plasma
cholesterol of 34.84% and 32.70% after administration by
gavage of 7S and 11S globulin, respectively, at a dose of 30
mg soy protein per day. Moreover, Adams et al. [28]
observed a 41% increase in HDL-C when isolated soy pro-
tein was introduced as a protein source in place of casein
and lactalbumin in the diet of monkeys, but there was no
improvement in lipoprotein levels or cardiovascular bio-
markers when the soy protein was replaced by 7S or 11S
globulin.
The reduction in plasma triglyceride levels in the ani-
mals receiving the glycinin was similar to that reported
by Aoyama et al. [29] in Sprague-Dawley rats fed isolated
soy protein or its hydrolyzates, which showed 24.81% and
33.33%, respectively, lower plasma triglycerides than the
casein control group. Fukui et al. [20,21] also showed
reduced levels of plasma triglycerides in Sprague-Dawley
rats fed a diet enriched with cholesterol and treated with
isolated soy protein, compared with the group that
received casein, the reduction varying between 18.18%
and 37.65%. It was suggested by Kingman et al. [30] that
the reduction in TG occurs independently of the level of
cholesterol.
The most significant result of the experiment was the
increase in plasma HDL-C in the HC+11S group, sug-
gesting that the 11S protein fraction may be involved in
regulatory processes: Perret et al. [31] mentions an
inverse relationship between the cholesterol content of
hepatocytes, mRNA and HDL-C levels. Rho et al. [32]
noted increased plasma concentrations of HDL-C in
Sprague-Dawley rats treated with peptides derived from
black soy, in various concentrations, relative to a casein
diet. The significant rise in HDL-C in the HC+11S
group was not observed in the HC+ROS group, since
statins are effective in lowering LDL-C, but have only a
modest effect in raising levels of HDL-C [10]. The
results of the HC+11S group suggest a protective role
for 11S globulin against the potential damage caused by
excess cholesterol in the body, since circulating HDL-C
has an antiatherogenic effect, in contrast to LDL-C,
which is a fraction considered to be an important cardi-
ovascular risk factor.
Among the groups studied, only in HC+11S the athero-
genic index did not differ from the STD group. In biolo-
gical terms, this is a significant evidence that 11S
globulin is a protective factor, improving the atherogenic
index in animals exposed to a hypercholesterolemic diet,
since a low LDL/HDL ratio and low levels of plasma tri-
glycerides are known to decrease appreciably the risk of
cardiovascular disease [33]. Rho et al. [32] observed a
reduction in the atherogenic index in Sprague-Dawley
rats treated with various concentrations of peptides
derived from soy, relative to the casein control group.
Similarly, in a human study, there was a lower LDL-C/
HDL-C ratio in individuals with moderate hypercholes-
terolemia who received isolated soy protein than in a
group consuming animal protein [34].
The reduction of the non-HDL-C fraction demon-
strated in the HC+ROS group is similar to literature
values for LDL-C in subjects taking the usual dose (5 to
10 mg) of rosuvastatin, which reduces LDL-C by 30 to
40% [9]. Also, we observed a significant reduction of
hepatic cholesterol in this group. However, this reduction
was completely inhibited, and the non-HDL-C level
exceeded that of HC group, when the 11S was given con-
comitantly with rosuvastatin (HC+11S+ROS). Thus, the
results of this study suggest a possible antagonistic effect
between the drug and the protein, as noted in the levels
of plasma total cholesterol, in non-HDL cholesterol frac-
tion, and the significant increase of cholesterol in the
liver, and that the separate administration of glycinin and
Table 4 The liver weight and hepatosomatic index (HSI) of experimental groups
STD HC HC+11S HC+ROS HC+11S+ROS
Liver (g) 10.90 ± 0.45
c 13.54 ± 0.36
b 17.63 ± 0.28ª 17.07 ± 0.92ª 17.14 ± 0.78ª
HSI (wt %) 3.79 ± 0.12
c 4.59 ± 0.14
b 5.91 ± 0.12ª 5.56 ± 0.27ª 5.68 ± 0.22ª
HSI = (liver weight/body weight × 100); STD = standard diet, AIN-93 Composition; HC = hypercholesterolemic diet: AIN-93 plus 1 g/100 g cholesterol and 0.5 g/
100 g cholic acid; HC+11S = HC diet + glycinin (300 mg/kg/day); HC+ROS = HC diet + rosuvastatin (10 mg/kg/day); HC+11S+ROS = HC diet + glycinin (300 mg/
kg/day) and rosuvastatin (10 mg/kg/day). Values represented as mean ± SEM. Different superscript letters in the same row indicate a significant difference (p <
0.05) between experimental groups.
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antagonism.
In relation to hepatic triglycerides, the groups HC+11S,
HC+ROS and HC+11S+ROS all showed lower levels
than the HC group. Previous studies [32,35] also showed
a reduction of hepatic triglycerides in rats treated with
soy protein, compared to rats fed on casein as protein
source, suggesting that this effect could result from the
regulation of SREBP-1c and its target genes involved in
fatty acid synthesis.
Possible mechanisms for the cholesterol-lowering
effect have been proposed [7,8], suggesting that soy pro-
tein could modulate the levels of LDL-C receptors,
while others [22,26,36], attribute this role to the pep-
tides formed during digestion of the protein. Such find-
ings are supported in clinical trials that ascribe reduce
LDL-C to the administration of peptides derived from
soy protein [37].
Significant progress has been recorded in the identifica-
tion of a specific mechanism leading to the reduction of
lipid concentrations by statins, particularly rosuvastatin,
namely the observed inhibition of 3-hydroxy-3-methyl glu-
taryl CoA reductase, the rate-limiting step in the synthesis
of cholesterol, which significantly reduces LDL-C [9].
Moreover, soy protein, in the form of isolated soy pro-
tein, or given as separate 7S and 11S proteins, has shown
satisfactory results, particularly in lowering total choles-
terol and increasing HDL-C, although its mechanisms of
action are still inconclusive. However, there is still no sig-
nificant synergistic effect, when drugs and functional food
are combined, that could be used to limit the dosage of
the drug, reducing the possible side effects and costs asso-
ciated with managing chronic diseases, among other
benefits.
In this study, when the effects of the isolated 11S pro-
tein (HC+11S group), the drug alone (HC+ROS) and
the combined treatment (HC+11S+ROS) were com-
pared, the beneficial effects of the separate treatments
were observed to disappear in the combination, showing
that there is no synergy between them.
In conclusion, the present results suggest the participa-
tion of glycinin in raising the plasma HDL-C and signifi-
cantly decreasing a number of pro-atherogenic factors in
rats that received the hypercholesterolemic diet, indicat-
ing that it may be considered a functional compound,
capable of improving the profile of plasma lipoproteins,
which may have an important role to play in reducing
the risk of heart disease. However, a possible drug-glyci-
nin interference shows that further investigation into the
mechanism of possible interactions between drugs and
food proteins is necessary, to avoid inhibition of the ther-
apeutic benefits and possible adverse effects. These find-
ings demonstrate the need for further research to clarify
the issue, since soy products are customary in the current
menu and could alter the pharmacological effect of any
treatment. Studies are in progress to identify the effects
of peptides derived from 11S and their role in cholesterol
metabolism.
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